Tepotinib
|
|
- CAS-Nr.
- 1100598-32-0
- Englisch Name:
- Tepotinib
- Synonyma:
- Tepotinib;EMD-1214063;Veledimex;CS-977;MSC2156119;EMD1214063,Tepotinib;epotinib(EMD 1214063);Tepotinib (EMD 1214063);EMD 1214063; EMD1214063;EMD-1214063|||MSC2156119
- CBNumber:
- CB72550731
- Summenformel:
- C29H28N6O2
- Molgewicht:
- 492.57
- MOL-Datei:
- 1100598-32-0.mol
|
Tepotinib Eigenschaften
- Siedepunkt:
- 626.5±65.0 °C(Predicted)
- Dichte
- 1.25
- storage temp.
- Store at -20°C
- Aggregatzustand
- Solid
- pka
- 8.93±0.10(Predicted)
- Wasserl?slichkeit
- ≥ 4.93 mg/mL in DMSO, <2.52 mg/mL in EtOH, <2.56 mg/mL in Water
- InChIKey
- AHYMHWXQRWRBKT-UHFFFAOYSA-N
- SMILES
- C(#N)C1=CC=CC(C2=NN(CC3=CC=CC(C4=NC=C(OCC5CCN(C)CC5)C=N4)=C3)C(=O)C=C2)=C1
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
|
Alarmwort |
Warnung |
Gefahrenhinweise |
Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
|
Sicherheit |
P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Tepotinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Tepotinib is a highly selective inhibitor against MET. In xenograft models, acquired resistance to EGFR TKIs via secondary EGFR T790 M mutations can be overcome with tepotinib treatment.
Verwenden
EMD 1214063 is a novel ATP-comptetitive inhibitor of the MET hepatocyte growth factor receptor and a novel kinase inhibitor and a therapeutic agent for neuroblastoma. Potent c-MET inhibitor.
Trademarks
Tepmetko
Mechanism of action
Tepotinib is a Kinase Inhibitor. The mechanism of action of tepotinib is as a Mesenchymal Epithelial Transition Inhibitor, and P-Glycoprotein Inhibitor.
Clinical Use
Tepotinib is currently being evaluated in combination with EGFR TKI gefitinib and also a separate trial in NSCLC patients with MET exon 14 skipping mutation and MET amplification.
Arzneimittelwechselwirkung
Tepotinib is indicated for the treatment of adult patients with
metastatic non-small cell lung cancer (NSCLC) who have
mesenchymal-epithelial transition (_MET_) exon 14 skipping alterations.
Stoffwechsel
Tepotinib is metabolized primarily by CYP3A4 and CYP2C8, with some
apparent contribution by unspecified UGT enzymes. The metabolite M506 is
the major circulating metabolite, comprising approximately 40.4% of
observed drug material in plasma, while the M668 glucuronide metabolite
has been observed in plasma at much lower quantities (~4% of an orally
administered dose). A total of 10 phase I and phase II metabolites have
been detected following tepotinib administration, most of which are
excreted in the feces.
Tepotinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Tepotinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 166)Lieferanten
1100598-32-0()Verwandte Suche:
- Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]
- 3-(1-(3-(5-((1-Methylpiperidin-4-yl)Methoxy)pyriMidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile
- 3-(1-(3-(5-((1-METHYLPIPERIDIN-4-YL)METHOXY)PYRIMIDIN-2-YL)BENZYL)-1,6-DIHYDRO-6-OXOPYRIDAZIN-3-YL)B
- 3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile
- Tepotinib (EMD 1214063)
- MSC2156119
- 3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile EMD-1214063
- EMD-1214063
3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile
- 3-(1-(3-(5-((1-Methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-
- Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)
- CS-977
- EMD 1214063; EMD1214063
- 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile
- epotinib(EMD 1214063)
- EMD1214063,Tepotinib
- Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl] USP/EP/BP
- EMD-1214063
- Tepotinib
- Veledimex
- EMD-1214063|||MSC2156119
- 1100598-32-0
- 100598-32-0
- 110050.98-32-0
- Inhibitors
- API